Literature DB >> 28683235

PROGNOSTIC VARIABLES AFFECTING PRIMARY TREATMENT OUTCOME FOR MEDULLARY THYROID CANCER.

Suhael Momin, Deborah Chute, Brian Burkey, Joseph Scharpf.   

Abstract

OBJECTIVE: Identifying prognostic risk factors and determining the efficacy of common surgical treatments is critical to determine optimal treatment strategies for patients with medullary thyroid carcinoma (MTC). The objective of this study was to review a contemporary institutional experience with MTC primary treatment with 2 goals: to identify prognostic factors that impact survival and to study the effect of neck dissection on those outcomes.
METHODS: This study was a retrospective case series of patients with MTC who underwent at least a total thyroidectomy with curative intent. Clinical parameters including tumor and nodal staging with corresponding pathology findings were identified. Survival endpoints included overall survival, disease-free survival, and biochemical cure.
RESULTS: Sixty-seven patients were included. The majority presented with early T-stage disease. Fifty (76%) patients were N0 at presentation. Seventeen (24%) had some evidence of neck disease on clinical examination or imaging. Forty (71%) achieved biochemical cure, and the 5-year biochemical recurrence-free survival for those cases was 86.5%. Among patients who had successful resection of all gross disease, 92% had no evidence of structural disease at 5 years. Overall survival was 91% at 5 years. Increased pre-operative calcitonin (Ct) level, primary tumor size, extrathyroidal extension, and neck metastases decrease the rate of biochemical cure. Larger tumor size increases the risk of structural disease recurrence and biochemical relapse after initial cure. The presence and number of neck metastases correlate with biochemical relapse. The presence of lateral neck nodes (pN1b) does not have different survival implications than centrally confined disease (pN1a).
CONCLUSION: This study shows increasing tumor size, increased Ct level, and cervical metastases are poor prognostic factors. Patients with large tumors, high Ct level, or unfavorable pathologic findings may warrant more aggressive initial treatment, although limitations of the study prevent any conclusion regarding the effect of neck dissection. ABBREVIATIONS: ATA = American Thyroid Association BRFS = biochemical recurrence-free survival CND = central neck dissection Ct = calcitonin DFS = disease-free survival MTC = medullary thyroid carcinoma OR = odds ratio OS = overall survival pCND = prophylactic CND.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28683235     DOI: 10.4158/EP161684.OR

Source DB:  PubMed          Journal:  Endocr Pract        ISSN: 1530-891X            Impact factor:   3.443


  7 in total

1.  Surgical selection and prognostic analysis in patients with unilateral sporadic medullary thyroid carcinoma.

Authors:  Jinming Zhang; Pengfei Gu; Dongmei Huang; Jingzhu Zhao; Xiangqian Zheng; Ming Gao
Journal:  Langenbecks Arch Surg       Date:  2022-06-24       Impact factor: 3.445

2.  Prognostic value of LODDS in medullary thyroid carcinoma based on competing risk model and propensity score matching analysis.

Authors:  Zhe Xu Cao; Xin Weng; Jiang Sheng Huang; Xia Long
Journal:  Updates Surg       Date:  2022-07-12

3.  CA19-9 as a Predictor of Worse Clinical Outcome in Medullary Thyroid Carcinoma.

Authors:  Renata Alencar; Daniel Barretto Kendler; Fernanda Andrade; Carla Nava; Daniel Bulzico; Cencita Cordeiro de Noronha Pessoa; Rossana Corbo; Fernanda Vaisman
Journal:  Eur Thyroid J       Date:  2019-04-02

4.  Static Prognostic Factors and Appropriate Surgical Designs for Patients with Medullary Thyroid Carcinoma: The Second Report from a Single-Institution Study in Japan.

Authors:  Yasuhiro Ito; Akira Miyauchi; Minoru Kihara; Takuya Higashiiyama; Mitsuhiro Fukushima; Akihiro Miya
Journal:  World J Surg       Date:  2018-12       Impact factor: 3.352

5.  Clinical Characteristics, Surgical Management, and Prognostic Factors of Medullary Thyroid Carcinoma: A Retrospective, Single-Center Study.

Authors:  Xin Wu; Binglu Li; Chaoji Zheng
Journal:  Technol Cancer Res Treat       Date:  2022 Jan-Dec

Review 6.  Management of lymph nodes in medullary thyroid carcinoma: A review.

Authors:  Ali Shaghaghi; Abolfazl Salari; Amirmohsen Jalaeefar; Mohammad Shirkhoda
Journal:  Ann Med Surg (Lond)       Date:  2022-09-03

7.  Risk Factors for Lateral Lymph Node Metastases in Patients With Sporadic Medullary Thyroid Carcinoma.

Authors:  Xin Wu; Binglu Li; Chaoji Zheng; Wei Liu; Tao Hong; Xiaodong He
Journal:  Technol Cancer Res Treat       Date:  2020 Jan-Dec
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.